Months after Amgen’s landmark KRAS approval, Chris Varma bags a crossover round for next-gen KRAS candidate

For years, mutant, cancer-fueling KRAS proteins were considered “undruggable.” That all changed in May, when Amgen’s KRAS-blocking drug Lumakras snagged the FDA’s first approval in the field. And now a slate of investors are betting $88.5 million on a Bay Area startup’s next-generation candidate.

Frontier Medicines has closed a...

Click to view original post